Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Summary

The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).

Timeline

Start

2017-03-27

Primary completion

2021-11-30

Completion

2023-06-16

Outcome

Met primary endpoint

registry Secukinumab 300 mg A1 (A1a+A1b) vs Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b); p <0.0001; Odds Ratio (OR) 16.8 NCT03020199 ↗

Publications

• Gudjonsson JE, Bier K, Gaulis S, Tsoi LC, Cardner M, Sarkar MK, Coon A, Cole C, Karner J, Fernandez A, Peters T, Eidsmo L, Iversen L, Jagiello P, Ferrero E, Kolbinger F, Lohmann F, Conrad C. Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results. J Allergy Clin Immunol. 2026 May 25:S0091-6749(26)00367-2. doi: 10.1016/j.jaci.2026.04.028. Online ahead of print.
• Iversen L, Langley RG, Gudjonsson JE, Eidsmo L, Narbutt J, Czajkowski R, Pinter A, Pink AE, Rivera-Diaz R, Gianchandani DA, Kolbinger F, Bao W, Gaillez C, Jagiello P, Conrad C. Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study. J Am Acad Dermatol. 2026 Mar 23:S0190-9622(26)00459-7. doi: 10.1016/j.jaad.2026.03.050. Online ahead of print.

Drugs

Indications